{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=69", "query": { "condition": "Immunity Disorders", "page": 69 }, "page_size": 10 }, "pagination": { "page": 69, "page_size": 10, "total_count": 21216, "total_pages": 2122, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=70&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=68&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T16:34:40.347Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05556616", "title": "A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Modakafusp alfa", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-01-12", "completion_date": "2024-06-04", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 14, "location_summary": "Sacramento, California • San Diego, California • Iowa City, Iowa + 8 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05556616" }, { "nct_id": "NCT06299592", "title": "Comparison of Microglial Activation in Severe Asthma and Healthy Controls", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Asthma" ], "interventions": [ { "name": "PET/MRI using [18F]FEPPA tracer", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 100, "start_date": "2024-03-06", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06299592" }, { "nct_id": "NCT00510471", "title": "Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genitope Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2007-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-03-18", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 9, "location_summary": "Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00510471" }, { "nct_id": "NCT00900263", "title": "S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma", "Plasma Cell Myeloma", "Precancerous Condition" ], "interventions": [ { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "biologic sample preservation procedure", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 375, "start_date": "2002-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-10-07", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 69, "location_summary": "Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 41 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hines", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900263" }, { "nct_id": "NCT03613363", "title": "Engineering Evaluation of the Helix Ventilator", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Respiratory Disease", "Pulmonary Disease", "Pediatric ALL" ], "interventions": [ { "name": "Helix Ventilator", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Philips Respironics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20, "start_date": "2018-06-06", "completion_date": "2021-09-07", "has_results": true, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 1, "location_summary": "Hawthorne, New York", "locations": [ { "city": "Hawthorne", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03613363" }, { "nct_id": "NCT05281393", "title": "PrEP2Prevent An Online PrEP Navigation and Activation Intervention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "PrEPresent", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Children's Hospital Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "26 Years", "sex": "ALL", "summary": "16 Years to 26 Years" }, "enrollment_count": 150, "start_date": "2021-01-28", "completion_date": "2024-01-03", "has_results": false, "last_update_posted_date": "2024-02-09", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05281393" }, { "nct_id": "NCT00003269", "title": "Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Drug/Agent Toxicity by Tissue/Organ", "Lung Cancer", "Lymphoma", "Ovarian Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Scripps Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "1998-02", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2011-01-10", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003269" }, { "nct_id": "NCT00682669", "title": "Asthma and Mindfulness-Based Stress Reduction (MBSR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "MBSR", "type": "BEHAVIORAL" }, { "name": "HLC", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Massachusetts, Worcester", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 83, "start_date": "2006-09", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2011-08-19", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 1, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00682669" }, { "nct_id": "NCT05298254", "title": "A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Herpes Simplex" ], "interventions": [ { "name": "Non-adjuvanted HSV formulation 1", "type": "BIOLOGICAL" }, { "name": "Non-adjuvanted HSV formulation 2", "type": "BIOLOGICAL" }, { "name": "Non-adjuvanted HSV formulation 3", "type": "BIOLOGICAL" }, { "name": "HSV formulation 1 with adjuvant 1", "type": "BIOLOGICAL" }, { "name": "HSV formulation 2 with adjuvant 1", "type": "BIOLOGICAL" }, { "name": "HSV formulation 3 with adjuvant 1", "type": "BIOLOGICAL" }, { "name": "HSV formulation 1 with adjuvant 2", "type": "BIOLOGICAL" }, { "name": "HSV formulation 2 with adjuvant 2", "type": "BIOLOGICAL" }, { "name": "HSV formulation 3 with adjuvant 2", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "HSVTI_F1", "type": "BIOLOGICAL" }, { "name": "HSVTI_F2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 505, "start_date": "2022-03-07", "completion_date": "2025-06-12", "has_results": false, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05298254" }, { "nct_id": "NCT00378105", "title": "Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2006-09", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-31T16:34:40.347Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00378105" } ] }